期刊文献+

非均相免疫法测定氨基端前B型钠尿肽的分析性能验证 被引量:2

Validation of analysis performance for N-terminal pro-B type natriuretic peptide determination by heterogeneus immunoassay
暂未订购
导出
摘要 目的验证非均相免疫法(HIA)测定氨基端前B型钠尿肽(NT-proBNP)的各项性能参数及参考范围并初步应用于临床。方法连续测定10次NT-proBNP的0水平校准品和3次低水平血浆,计算功能灵敏度。采用美国临床实验室标准化委员会(NCCLS)EP6-A、EP15-A、EP7-P提供的方案对该方法的线性范围、精密度、干扰进行验证,并与电化学发光法进行比对及偏差评估。测定345名表面健康人及无相关疾病人群的NT-proB-NP,对参考范围进行验证。测定63例慢性心力衰竭患者及急性冠状动脉综合征患者的NT-proBNP水平并评价其分布。结果本方法功能灵敏度为22.3 ng/L;线性范围为45-28 150 ng/L,r=0.998 6;批内不精密度为3.3%-5.2%,总不精密度为5.4%-7.1%;胆红素、血红蛋白、乳糜在试剂说明书提供的浓度对测定均无明显干扰(平均差异均〈10%);与电化学发光法比对,相关方程为Y=0.81X-72.9,r=0.999,平均百分偏差为-11.6%。NT-proBNP随年龄增加呈上升趋势,65岁以上各年龄组差异有统计学意义(P均〈0.05);各年龄组女性显著高于男性(P=0.015)。结论HIA测定NT-proBNP的各项性能指标良好,符合临床需要。目前各年龄性别组参考范围接近国外人群,适用于本实验室。 Objective To validate the various performances of N-terminal pro-B type natriuretic peptide ( NT-pro BNP) hy heterogeneus immunoassay (HIA) method and try its preliminary clinical application. Methods The zero calibrator of NT-proBNP was tested 10 times and low level plasma was tested 3 times in the same analytical run for functional sensitivity. Linearity, imprecision,accuracy,interferences and reference interval were studied according to National Committee for Clinical Laboratory Standards (NCCLS) EP6-A, EP15-A and EP7-P protocol. Compared with electrochemiluminescent immunoassay (ECLIA) appraised the bias. The levels of NT-proBNP in 345 apparently healthy individuals and no chronic heart failure (CHF) patients were detected for verifying reference range. The levels of NT-proBNP in 63 patients with CHF and acute coronary syndrome (ACS) were detected mad its distribution was evaluated also. Results The functional sensitivity of this method was 22.3 ng/L. The linearity range was 45 - 281 50 ng/L, r = 0. 998 6. Within and total coefficient of variation (CV) % were 3.3 % - 5.2% and 5.4% - 7.1%. Bilirubin, turbidity and hemoglobin had no effect on evaluated methods( mean differences 〈 10% ). Compared with ECLIA, Y =0. 81X - 72. 9, r =0. 999, average percent error was - 11.6%. The level of NT-proBNP increased with the age going. Significant difference was seen among the groups over the age of 65 (P 〈 0.05 ). NT-proBNP ievel in females was higher than that in males in each age group (P=0.015). Conclusions The HIA method used to detect the NT-proBNP level has good performance and corresponds to clinical needs. Reference ranges of different age and sex groups are closed to that of foreigners, and are used in our laboratory.
出处 《检验医学》 CAS 北大核心 2007年第6期627-632,共6页 Laboratory Medicine
关键词 氨基端前B型钠尿肽 非均相免疫法 分析性能 N-terminal pro-B type natriuretic peptide Heterogeneus immunoassay Analysis performance
  • 相关文献

参考文献16

  • 1周琰,陶青,潘柏申.B型利钠肽在心脏疾病中的应用[J].诊断学理论与实践,2004,3(5):376-381. 被引量:18
  • 2Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure [J]. Euro Heart J, 2001, 22(17) : 1527-1560.
  • 3Hunt SA. Abraham WT, Chin MH, et al. ACC/ AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult [J].Circulation, 2005, 112(12): e154-e235.
  • 4李志艳,徐国宾,夏铁安.2004年美国临床生化科学院心肌生化标志物应用指南(草案)介绍[J].诊断学理论与实践,2004,3(5):388-392. 被引量:10
  • 5National Committee for Clinical Laboratory Standards. Evaluation of the linearity of quantitative measurement procedures: a statistical approach [S]. EP6-A. Wayne, PA: NCCLS, 2003.
  • 6National Committee for Clinical Laboratory Standards. User demonstration of performance for precision and accuracy [S]. EP15-A. Wayne, PA : NCCLS, 2001.
  • 7National Committee for Clinical Laboratory Standards. Interference testing in clinical chemistry.[S]. EP7-P. Wayne, PA: NCCLS, 1986.
  • 8National Committee for Clinical Laboratory Standards. How to define and determine reference intervals in the clinical laboratory [S]. C28-A2. Wayne, PA: NCCLS, 2000.
  • 9邱玲,程歆琦,鄢盛恺,沈瑛,刘茜,刘荔,刘福成,葛增梅.临床化学方法验证与表格化管理[J].现代检验医学杂志,2006,21(4):5-9. 被引量:10
  • 10National Committee for Clinical Laboratory Standards. Evaluation of precision performance of clinical chemistry devices [S]. EP5-A. Wayne, PA: NCCLS, 1999.

二级参考文献120

  • 1Bozkurt B,Mann DL. Use of biomarkers in the management of heart failure. Are we there yet? Circulation ,2003,107 : 1231-1233.
  • 2White HD,French JK. Use of brain natriuretic peptide levels for risk assessment in non-ST-elevation acute coronary syndromes. J Am Coll Cardiol,2003,42 : 1917-1920.
  • 3Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure. European Society of Cardiology. Euro Heart J,2001,22 : 1527-1560.
  • 4Hunt SA,Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation ,2005,112 :e154-e235.
  • 5de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet ,2003,362:316-322.
  • 6Yeo KTJ, Wu AHB, Apple FS, et al. Muhicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta,2003,338 : 107-115.
  • 7Vasan RS. Expanding indications for natriuretic peptides:impottance of better new (research) protocols. Am Heart J ,2004,148:743-746.
  • 8Panteghini M,Pagani F,Yeo KTJ,et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem,2004,50:327-332.
  • 9Jaffe AS, Katus H. Acute coronary syndrome biomarkers: the need for more adequate reporting. Circulation ,2004,110 : 104-106.
  • 10Redfield MM, Rodeheffer R J, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration : impact of age and gender. J Am Coll Cardiol,2002 ,40 :976-982.

共引文献169

同被引文献12

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部